Screen & Treat
Program
A complete solution for cervical cancer diagnostics and treatment
Screen & Treat Program
treatment solution
Overcoming the challenges in cervical
cancer
Impacting lives and changing outcomes for women worldwide
Cervical cancer is the 4th most common cancer in women worldwide, with more than 300,000 women dying from it each year.
These deaths could have been easily prevented by timely screening and treatment.
Accessibility and loss to follow-up are a major challenge in reducing the high death toll.
60% of women screened in an initial visit for PAP or HPV, do not return for treatment.
Impacting lives and changing outcomes for women worldwide
Cervical cancer is the 4th most common cancer in women worldwide, with more than 300,000 women dying from it each year.
These deaths could have been easily prevented by timely screening and treatment.
Accessibility and loss to follow-up are a major challenge in reducing the high death toll.
60% of women screened in an initial visit for PAP or HPV, do not return for treatment.
A Holistic Approach to Women’s Health
At mobileODT, we recognize that a medical device system needs to be as flexible as its customers are unique.
We offer cervical cancer practitioners the convenience of having multiple needs met by a single supplier. Our comprehensive solution allows practitioners the flexibility to engage with mobileODT for all their cervical cancer needs.
mobileODT offers a full turnkey diagnostic and treatment program utilizing the EVAPro digital colposcope and theThermoGlide, for thermocoagulation treatment of precancerous lesions.
The single sitting “screen and treat” program allows us overcome the major challenge of loss to follow-up.
The MobilleODT Single Visit Program
Overcoming loss to follow-up within a single visit
High proportions of loss to follow-up for cervical cancer patients have been reported in low and mid range income countries, ranging between 41–69%.2,3. The MobileODT screening and treatment solutions reduces loss to follow up and increasing efficacy in diagnosis and treatment programs
Want to Know
More About our
Products?
The MobilleODT Single Visit Program
Overcoming loss to follow-up within a single visit
HPV-16/18 genotyping or cytological examination has been recommended to triage for immediate colposcopy in many national screening guidelines. This method offers greater sensitivity than cytological examination alone and better specificity than referring all women with HPV for colposcopy. Referring all women with high-risk HPV to colposcopy would likely lead to overtreatment and incur high healthcare costs.
High proportions of loss to follow-up for cervical cancer patients have been reported in low and mid range income countries, ranging between 41–69%.2,3. The MobileODT screening and treatment solutions reduces loss to follow up and increasing efficacy in diagnosis and treatment programs